This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

Choose ELIQUIS® for your patients with NVAF

ELIQUIS® (apixaban) – an oral, direct factor Xa inhibitor - is indicated for:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)1

Robust, clinical evidence for ELIQUIS in patients with NVAF

ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1

Footnotes:

  • * There is limited experience of treatment with ELIQUIS at the recommended dose for NVAF patients when used in combination with antiplatelet agents in patients with ACS and / or undergoing PCI after haemostasis is achieved. ELIQUIS should be used with caution when co-administered with aspirin and / or P2Y12 inhibitors because these medicinal products typically increase the bleeding risk.1
  • ACS = Acute Coronary Syndrome   DVT = Deep Vein Thrombosis   NVAF = Non-Valvular Atrial Fibrillation   NYHA = New York Heart Association   PE = Pulmonary Embolism   PCI = Percutaneous Coronary Intervention   TIA = Transient Ischaemic Attack   VKA = Vitamin K Antagonist

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.ie.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.
  3. Lopes RD et al. N Engl J Med 2019; 365: 883–891.
  4. Lip GH et al. Stroke. 2018; 49: 2933–2944.

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com